C regulatory T (T R ) cells represent a unique lineage of thymically generated lymphocytes capable of powerfully suppressing immune responses. A large body of experimental data has now confirmed the key role played by these cells in the maintenance of self-tolerance. Increasingly, the importance of these cells is also being recognized in a host of other clinically relevant areas such as transplantation, tumour immunity, allergy and microbial immunity. Additionally, it is also possible to generate T R cells by using a variety of ex vivo experimental approaches. We will focus here on harnessing the suppressive abilities of both these families of regulatory cells and how this should give us access to a potent cell-based immunotherapy appropriate for clinical application.
INTRODUCTION
The random nature of T cell receptor (TCR) generation and its selection on self-major histocompatability complex (MHC) inevitably leads to the appearance of deleterious autoreactive clones. The vast majority of such cells are purged in the thymus during the processes of negative selection. This process is, however, imperfect, as there is abundant experimental evidence that harmful autoreactive T cells can be activated outside of the thymus by the administration of adjuvant and self-proteins (Zamvil et al. 1985; Salamero et al. 1987; Myers et al. 1997) . This seems also to be the case in humans, wherein it is possible to clone-out autoreactive T cells from the periphery of both normal individuals and those with manifest autoimmunity (Burns et al. 1983; Allegretta et al. 1990; Ota et al. 1990) . Recent studies using MHC Class II tetramers have indeed unequivocally demonstrated that peripheral T cells recognizing self-antigen exist in normal humans (Danke et al. 2004) . The fact that perfectly healthy individuals can harbour autoaggressive cells connotes the existence of tolerance mechanisms operational in the periphery. Textbooks classically divide such mechanisms into immunological ignorance, immunological privilege, anergy/deletion and dominant tolerance, though in reality the distinctions are probably not nearly so clear-cut. In recent years, the role played by dominant tolerance mediated through the action of regulatory T (T R ) cells has come to pre-eminence. We herein focus on this latter mechanism of peripheral tolerance and investigate the clinical potential held by the successful therapeutic manipulation of T R cells.
NATURALLY OCCURRING AND ADAPTIVE REGULATORY CELLS Broadly speaking, CD4
C T cells possessing the ability to suppress immune responses can be divided into two types: naturally occurring and adaptive regulatory cells (figure 1; Bluestone & Abbas 2003) . Naturally occurring regulatory cells (defined hereafter as 'T R cells') are generated in the thymus under poorly understood conditions. Adaptive regulatory cells (also referred to variously as 'Th3' or 'Tr1') are generated outside of the thymus under specialized activation conditions. We will consider each of these populations in turn.
(a) Naturally occurring regulatory T cells Experimental evidence for T R cells has been suggested by animal models of autoimmune disease for many years (Sakaguchi 2000a) . One of the earliest clues to the existence of T R cells (though it was not appreciated as such at the time) was found when neonatal thymectomy of certain strains of mice was shown to elicit autoimmune oophoritis (Nishizuka & Sakakura 1969) . Thymectomy of adult rats and mice followed by fractionated X-irradiation could also produce autoimmune disease (Penhale et al. 1973; Sakaguchi et al. 1994) . Crucially, it was shown that the induction of such autoimmunity could be prevented by the transfer of normal CD4
C splenocytes or CD4 C CD8 K thymocytes (Sakaguchi et al. 1994) . Collectively, these data were strongly suggestive of the existence of a thymically produced suppressive T cell population, which was responsible for the establishment and maintenance of peripheral self-tolerance. These regulatory cells appeared to migrate out from the thymus at a relatively late stage compared to conventional/autoreactive T cells (more than 3 days after birth in mice). This lag-phase enabled the experimental induction of autoimmunity by the careful timing of neonatal thymectomy or an immunosuppressive regimen which preferentially targeted the suppressive T cell population.
Attempts were subsequently made to characterize these suppressor or T R cells as they came to be known, by identifying the surface phenotype that harboured regulatory activity. Initially, CD5 was proposed as a marker for T R cells by demonstrating that otherwise normal lymphocytes depleted of CD5 high CD4 C cells elicited autoimmunity when transferred into athymic nude mice (Sakaguchi et al. 1985) . Unfractionated CD4 C cells (which contain CD5 high expressers) prevented the induction of autoimmunity when cotransferred along with the CD5 low cells, implying that T R cells were contained specifically within the CD5 high compartment. Similarly, the CD45RB molecule appears to divide T cells into two distinct functional subsets: CD45RB high and CD45RB low cells (Powrie et al. 1993) . The CD45RB high population triggers inflammatory bowel disease (IBD) when transferred to lymphopenic mice, by eliciting an immunopathological reaction against normal gut-flora, whereas the CD45RB low counterpart prevents such disease induction. To date, the most functionally useful surface marker for T R cells has proven to be their constitutive expression of the IL-2 receptor a-chain (IL-2R), CD25 (Sakaguchi et al. 1995) . Approximately 5-10% of CD4 C peripheral T cells constitutively express CD25 in normal naive mice and healthy humans (Sakaguchi et al. 1995; Baecher-Allan et al. 2001) . In mice, these CD25 C T cells are found in both the CD5 high and CD45RB low T cell fractions. Indeed, transfer of CD25-depleted CD4 C T cells to athymic mice elicits a variety of autoimmune diseases such as thyroiditis, gastritis and insulitis, whereas co-transfer with CD25 C CD4 C cells inhibits such disease development (see figure 2) .
Interestingly, CD25 does not appear to be merely a marker for T R cells, but rather reflects an absolute dependence on IL-2 for their peripheral maintenance and function. This is dramatically demonstrated by the loss of T R cells and consequent autoimmunity which occurs if IL-2 signalling is perturbed, e.g. in the case of knock-out mice (Almeida et al. 2002; Malek et al. 2002) or antibody blockade (Setoguchi et al. 2005) . In vitro T R cells are anergic to conventional TCR stimuli but this is not observed physiologically in vivo where they show a seemingly high rate of turnover, which again probably reflects a dependency on IL-2 (Takahashi et al. 1998; Almeida et al. 2002; Setoguchi et al. in press) .
More recently a number of other cell surface molecules have been shown to be associated with T R cells, among them: CTLA4 (CD152), a E b7-integrin (CD103), glucocorticoid induced TNF family receptor (GITR) and neuropilin-1 (a receptor more usually involved in axon guidance) (Read et al. 2000; Takahashi et al. 2000; Lehmann et al. 2002; McHugh et al. 2002; Shimizu et al. 2002; Bruder et al. 2004) . It should be noted, however, that no single uniquely expressed cell surface molecule has thus far been identified for T R cells and in many cases relatively specific molecules such as GITR or CD25 are upregulated to high levels on activated non-regulatory T cells as well. This problem is made especially acute in humans who naturally show large numbers of activated CD25 C T cells and, therefore, a definitive identification is usually only possible by sorting the highest CD25 C expressers . Experimental evidence now also appears to demonstrate the existence of a small T R population lacking CD25 but showing high levels of GITR expression (Lehmann et al. 2002; Nishimura et al. 2004; M. Ono, personal communication) . Where these CD25 K CD4 C T R cells Figure 1 . Relationship of thymically and extrathymically generated regulatory cells. T cells emerge from the thymus as either regulatory cells (T R ) or conventional naive T cells (Th0). The pathological responses of autoreactive effector cells (T E ) can be suppressed by the action of both thymically (T R ) and peripherally (Tr1/Th3) generated regulatory cells. The developmental relationship between the two classes of regulatory cells still needs to be fully clarified but some evidence suggests that Th0 are able to differentiate into T R cells in the periphery under special conditions. fit into overall T R cell taxonomy remains unclear, but it further highlights the difficulties involved in unambiguously pinpointing natural T R cells for clinical application. The molecular understanding of T R cell biology took a leap forward following the delineation of the functional and developmental role played by the transcriptional repressor Foxp3. The importance of Foxp3 was first appreciated in studies using the Scurfy mouse. This mouse exhibits a fatal X-linked lymphoproliferative disease characterized by a very severe multi-organ immunopathology, allergy and IBD (Lyon et al. 1990) . The Scurfy phenotype is very similar to the human immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome both in presentation and severity, and mutations in the Foxp3 (FOXP3 in humans) gene were found to underlie both conditions (Bennett et al. 2001; Brunkow et al. 2001; Wildin et al. 2002) . The overt similarities seen between mutations in Foxp3 and experimental depletion of CD25 C CD4 C cells led to its identification as a key transcription factor involved in the development and function of T R cells (Fontenot et al. 2003; Hori et al. 2003; Khattri et al. 2003) . These mouse studies demonstrated Foxp3 mRNA and protein to be expressed specifically in CD25 C CD4 C T cells and, in contrast to the cell surface markers used to date, was never observed in conventional T cells following activation or differentiation to Th1 or Th2. Critically, and probably most significantly from a potential therapeutic perspective, retroviral transduction of Foxp3 to both mouse (Hori et al. 2003) and human (Yagi et al. 2004 ) non-regulatory CD4
C cells bestowed them with a fully functional T R cell phenotype; i.e. they became anergic, expressed T R cell surface markers and could mediate suppression both in vitro and in vivo. Collectively, the data from mice show Foxp3 to be not only a seemingly unambiguous marker for naturally occurring T R cells, whose genetically programmed expression is sufficient to drive their development and function, but also demonstrates them to be a genuinely distinct lineage rather than simply another activation state of conventional T cells. Essentially, a similar pattern of FOXP3 expression is seen in human cells (Yagi et al. 2004) as in the mouse, although one report has suggested an important difference: both FOXP3 mRNA and protein appear to be induced in conventional CD4
C T cells following activation . However, it should be noted that a second study was unable to observe this effect in human cells and reported a largely stable expression of FOXP3 (Yagi et al. 2004) . By way of a possible resolution, one can speculate that the appearance of FOXP3
C in the human cell cultures represents a selective expansion of a small contaminating FOXP3 C population. We will return to this confusion later on.
The mechanism of T R cell suppression remains rather confusing. Abundant in vitro evidence has demonstrated that T R cells require cell contact to mediate suppression, with no suggestion of any role played by soluble factors (Takahashi et al. 1998; Thornton & Shevach 1998; Sakaguchi 2004) . Candidate molecules employed by T R cells to mediate suppression have been suggested, e.g. CTLA4 and cell surface TGF-b (Nakamura et al. 2001; Fallarino et al. 2003; Munn et al. 2004; Paust et al. 2004 ) and the CD4 homologue LAG-3 (Huang et al. 2004) ; however, none of these findings appear to be definitive. For instance, in the case of CTLA4, T R cells from CTLA4 K/K mice appear to be just as effective as their wild-type counterparts at mediating suppression in vitro (Takahashi et al. 2000; Tang et al. 2004a) . In vivo, however, there appears to be an indispensable role for soluble factors such as IL-10 and TGF-b in T R cell mediated control of immunopathology or allograft rejection (Powrie et al. 1996; Asseman et al. 1999; Hara et al. 2001; Singh et al. 2001; Maloy et al. 2003) . The importance of both these cytokines to T R cell suppressive functions in vivo can be clearly demonstrated by using cells from IL-10 K/K mice or blocking TGF-b and/or IL-10R with monoclonal antibodies (Chen et al. 1994; Roncarolo et al. 2001; Weiner 2001 ). Th3 cells were first cloned-out from the mesenteric lymph nodes of mice orally tolerized with myelin basic protein. The majority of such cells produce TGF-b, low/absent IL-10 and varying levels of Th2 cytokines and are able to suppress the induction of experimental autoimmune encephalitis (EAE). Th3-like cells have also been shown to be important in the control of a variety of other experimental autoimmune disease models (Weiner 2001) . Some clinical data has also observed a perturbation of TGF-b/Th3 function in some cases of human autoimmunity and allergy (Andersson et al. 2002; Perez-Machado et al. 2003) .
Tr1 cells were first generated under conditions involving mouse T cell activation in the presence of the immunomodulating cytokine IL-10 ( Groux et al. 1997) . Such cells secrete a pattern of cytokines quite distinct from that of the more usual Th1-Th2 profile and are characterized by high levels of IL-10 and generally low levels of TGF-b and IL-5. Moreover, Tr1 cells are anergic, functionally suppressive in vitro and are able to prevent the development of experimentally induced Th1 autoimmune diseases such as colitis (Groux et al. 1997) . A variety of other ex vivo experimental treatments have also led to the generation of Tr1-like cells, suppressive in vitro or in vivo, chief among these being the stimulation of normally nonsuppressive conventional CD4
C T cells by immature or cytokine modified dendritic cells (DC) ( Jonuleit et al. 2000; Sato et al. 2003; Verhasselt et al. 2004) . A common principle which may underlie such tolerizing DC is their unique pattern of stimulatory ligands, e.g. high MHC class II coupled to low costimulation (CD80 and CD86). A recent paper, with potentially important therapeutic implications, apparently identified a DC subset responsible for the generation of regulatory cells in vivo ( Wakkach et al. 2003) . Such DCs possessed a plasmacytoid morphology and expressed the CD45RB molecule. Other molecular signals which seem to play a role in Tr1 generation (not necessarily in the presence of DC) appear to be those acting through CD2, Notch-1 and interestingly the complement receptor CD46 (Hoyne et al. 2001; Wakkach et al. 2001; Kemper et al. 2003; Vigouroux et al. 2003; Yvon et al. 2003) . Finally, it is also possible to generate regulatory cells ex vivo by treating human and mouse T cells with the pharmacological immunosuppressants vitamin D 3 and dexamethasone (Barrat et al. 2002; Vieira et al. 2004 ). However, these particular cells also appear to be somewhat distinct from the previously characterized Tr1/Th3 cells in that they appear to secrete solely IL-10 as well as retain a robust proliferative capacity; such characteristics would certainly be desirable for their use in any therapeutic capacity.
(c) What is the relationship between naturally occurring T R cells and adaptive regulatory cells such as Tr1 or Th3 cells? A degree of uncertainty persists as to the precise developmental relationship between thymically generated T R cells and peripherally generated adaptive regulatory cells. Although both CD4
C regulatory cell types are certainly suppressive in one form or another, it is likely that T R cells and adaptive regulatory cells actually represent distinct cell types, with any similarities being a result of convergence rather than a closely shared lineage. A number of observations lead to this conclusion. Firstly, T R cells and adaptive regulatory cells appear to differ fundamentally in their in vitro suppressive mechanisms, with the former requiring cell contact and the latter utilizing secreted IL-10 and TGF-b either alone or in combination. Secondly, it is still unclear which of the peripherally generated regulatory cells express Foxp3, which is now Table 1 . Experimental approaches to the extrathymic generation of (adaptive) regulatory T cells.
(A large number of experimental approaches have been shown to induce regulatory cells outside of the thymus. They may take the form of ex vivo treatment (e.g. the addition of specific cytokines or pharmacological compounds in vitro) or in vivo induction (e.g. oral tolerance). The relationship among these various regulatory cell types is still largely unclear as is their relationship to thymically generated CD25 C CD4 C T R cells, though the approaches (7) and (8) (2004) thought to be critical for the generation of natural T R cells. To be fair, a comprehensive analysis of Foxp3 in all the various types of adaptive regulatory cells has not yet been made, although a couple of studies have suggested that Tr1 cells generated on immature DC (Levings et al. 2004) or by treatment with vitamin D 3 -dexamethasone (Vieira et al. 2004 ) are both Foxp3 negative. Such results would imply that they represent a differentiation state quite distinct from T R cells. One could conclude then that extra-thymically generated regulatory cells represent a heterogeneous assemblage whose primary physiological function would most likely be the homeostatic control of immune responses to exogenous antigens. Such adaptive regulatory cells would be generated concurrent/subsequent to a microbial infection with the aim of mitigating immunopathology. The corollary of this is that adaptive regulatory cells are an alternative lineage of conventional CD4 C helper T cells, akin to Th1 or Th2. In contrast, thymically generated CD25 C CD4 C T R cells, by virtue of their Foxp3 expression, can be considered a de facto terminally differentiated lineage primarily, but not exclusively, committed to the maintenance of selftolerance. Unfortunately this rather neat compartmentalization is challenged by recent data suggesting that T R cells, as defined by Foxp3 expression and suppressive function, can also be generated extrathymically under particular conditions (Chen et al. 2003; Apostolou & Von Boehmer 2004) . The addition of exogenous TGF-b to ex vivo cultures of conventional non-T R cells results in the generation of suppressive Foxp3 C T R -like cells (Chen et al. 2003 ; our own unpublished observations). Similarly, a 'low-zone tolerance' approach involving carefully controlled dosing of minute quantities of systemic antigen generates Foxp3
C regulatory cells in otherwise T R cell-deficient and thymectomized mice (Apostolou & Von Boehmer 2004) . Therefore, if one accepts Foxp3/ FOXP3 to be an unambiguous marker for T R cells then the ineluctable conclusion would be that the extrathymic generation of 'true' T R cells can, in actual fact, occur under very particular conditions. The finding in the human system that FOXP3 C cells can be generated in vitro following standard TCR-mediated stimulation of conventional CD4 C T cells ) is similarly problematic to the formulation of a clear distinction between thymically and extrathymically generated regulatory cells. From a therapeutic perspective such epistemological questions may not even be important; what matters is the ability to controllably generate regulatory cells that are able to suppress harmful immunopathology.
EXPERIMENTAL EVIDENCE FOR REGULATORY CELLS AS A POTENTIAL IMMUNOTHERAPY
(a) Autoimmunity and allergy As described in the previous sections there is an abundance of evidence that T R cells are engaged in the maintenance of self-tolerance and both T R and adaptive T R cells can be used to control immunopathology in various animal models of experimental autoimmunity (Roncarolo et al. 2001; Sakaguchi 2004 ). Importantly, a focus on T R cell therapy is validated by a small but growing body of clinical data showing that their dysfunction may be relevant to human autoimmune disease and allergy Taylor et al. 2004) . For example, in the case of multiple sclerosis patients, there seems to be normal numbers of peripheral CD25
C T R cells but their in vitro suppressive capacity is impaired relative to normal controls Viglietta et al. 2004) . A similar impairment of T R cell function has also been reported in patients with rheumatoid arthritis (Ehrenstein et al. 2004) .
Allergic diseases such as asthma, rhinitis and atopic dermatitis are thought to result chiefly from the differentiation and activation of Th2 cells in response to allergens. In vitro studies have shown that CD25 C CD4 C cells are also able to suppress Th2 responses; therefore, moderating the reaction to allergens is potentially within the T R cell remit of control (Stassen et al. 2004) . Suppression of allergic responses appears to occur primarily through the action of IL-10, most likely secreted by T R cells, whether natural or adaptive. IL-10 can suppress both the innate (mast cells, basophils and eosinophils) and adaptive (Th2 and B cell secretion of IgE) arms of the allergic response . Several clinical studies have indeed found an association between diminished levels of patients' T cell IL-10 and both asthma and atopic dermatitis (Borish et al. 1996; Koning et al. 1997) . More direct evidence for the role of regulatory cells in allergy is shown by a relative preponderance of allergen-specific Tr1-like cells in healthy non-atopic individuals but Th2 cells in allergic individuals . Similarly, the in vitro ability of CD25 C CD4 C cells to inhibit allergenspecific responses appears diminished in atopic individuals (Ling et al. 2004) . Most interestingly, this relative impairment of suppression was even more pronounced in CD25 C CD4 C cells isolated from hayfever sufferers during the grass pollen season than out of it. Whether the majority of human autoimmune and allergy cases implicate a component of T R cell dysfunction remains to be seen.
Although no clinical therapies involving T R cells have yet been attempted, some recent works using nonobese diabetic (NOD) mice (a model of autoimmune diabetes) have suggested that such an approach may well be successful (Tang et al. 2004b; Tarbell et al. 2004) . The authors of these studies were able to demonstrate not only a large in vitro expansion of T R cells but, most excitingly, the ability to bring ongoing type 1 diabetes (T1D) under control by the transfer of T R cells combined with islet transplantation. However, in the case of one of the studies, in vivo suppression of diabetogenic cells was only possible by using pancreatic islet antigen-specific T R cells, presumably because only a tiny fraction of cells from a normal polyclonal T R population would actually home to the pancreas and be able to exert any meaningful suppression. A similar 'specificity' limitation was found for the suppression of T1D using Foxp3 transduced cells (Jaeckel et al. 2004 ). This has significant implications for any clinical immunotherapy, since it demands the identification of islet reactive human T or T R cell clones.
(b) Transplantation
The Holy Grail of organ transplantation would be to establish tolerance to the foreign graft as effectively as that to self-tissues, but without the need for generalized immunosuppression (Wood & Sakaguchi 2003) . One way in which this ambitious goal may be realized is through the exploitation of T R cells. BALB/c nude mice transplanted with B6 skin and subsequently reconstituted with normal BALB/c T cells show robust graft rejection, which is accelerated by the removal of CD25
C cells from the reconstituting T cell population (Sakaguchi et al. 1995) . This finding suggests that the small population (5-10%) of T R cells resident in the BALB/c T cell transfer is able to somewhat retard the normal allogeneic response and, therefore, increasing the numbers (or function) of transferred T R cells may engender a permanent state of allograft survival. This does indeed appear to be the case, since the transfer of highly purified CD25 C CD4 C T R cells to nude recipients, either prior or simultaneous to reconstitution with naive T cells, significantly prolongs graft survival (Sakaguchi et al. 2001) . Furthermore, permanent allograft survival may be established by the transfer of large doses of T R cells. The scarcity of T R cells means that obtaining large numbers (as would be required for clinical applications) is highly problematic. However, it is possible to expand, in vitro, purified CD25 C T R cells on donor-specific splenocytes (plus IL-2 to break T R cell in vitro anergy) prior to in vivo transfer (Sakaguchi et al. 2001; Trenado et al. 2003; Nishimura et al. 2004) . As well as generating large numbers of T R cells for potential in vivo use, such expansion has the additional advantage of selectively expanding the donor-responsive cells and, hence, improving the efficiency of suppression. Potentially T R cells may also be expanded in vitro using mature DC yet still retain their suppressive functions, which may represent an appealing technique for therapy (Yamazaki et al. 2003; Tarbell et al. 2004) .
T R cells are also able to expand on an allograft in vivo, in much the same way as normal alloreactive T E (effector) cells; however, in the case of T R cells this expansion is non-destructive and beneficially suppressive (Nishimura et al. 2004) . Experimental skin transplantation systems have clearly demonstrated that in vivo pre-expansion of regulatory cells on an allograft prior to exposure to alloreactive CD25 K cells significantly improves graft survival, when compared to a simultaneous transfer of both CD25
C T R and CD25 K cells (Nishimura et al. 2004) . T R cells themselves home to, and can actually be found within, the graft proper (Graca et al. 2002; our own unpublished observations) and once this population is established the graft is very stably tolerated, whereas a fresh graft of identical haplotype shows a lower survival (figure 3; Nishimura et al. 2004) . Rather than being a systemic phenomenon, T R cell-maintained tolerance instead appears to take the form of stable 'islands' of suppression. From the standpoint of immunotherapy, such properties are ideal, since it would engender a state of localized tolerance without the dangers of generalized immunosuppression. This process is summarized in figure 4 .
A large number of studies have also been able to induce prolonged graft survival by the administration of mAbs to various T cell-and antigen presenting cell (APC)-associated molecules such as CD4, CD8, CD40L, CD80 and CD86 (Hara et al. 2001; Taylor et al. 2001; Graca et al. 2002; Nathan et al. 2002; Taylor et al. 2002; Cobbold et al. 2004 ). Many such studies employing mAbs implicate the role of regulatory cells in maintaining graft tolerance, and interestingly there is a suggestion that co-receptor blockade by non-depleting anti-CD4 mAbs in particular may act by inducing T R cells de novo Karim et al. 2004; . Non-depleting anti-CD4 may yet lend itself as the T E cell-specific form of immunosuppression depicted in figure 4 ; however, the optimization of anti-CD4 for the clinic has still not been achieved.
Bone marrow transplantation for the treatment of haematological malignancies presents particular clinical problems. Such treatments must carefully balance the immunosuppression of potentially lethal graft versus host disease (GVHD) yet preserve a robust and beneficial lethal graft versus tumour (GVT) response. T R cells have also been shown to be ). Approximately 70% of such grafts are retained more than 100 days. Mice with original surviving grafts received fresh grafts of identical haplotype (B6 2 0 ) and third party grafts (C3H) and survival examined (a). Animals maintained a high localized tolerance to the original graft but only partially so to the secondary graft of identical haplotype, which was rejected albeit at a slower tempo than the third party graft (b) (kindly reproduced with permission from Oxford University Press).
potentially effective in such a setting. Initially, studies demonstrated that the transfer of donor-type CD25 C CD4 C T R cells with bone marrow precursor cells could markedly protect from lethal GVHD and this effect was dependent in part on IL-10 production (Hoffmann et al. 2002) . In subsequent related studies, it was shown that T R cells were able to not only protect from GVHD following bone marrow transplantation, but also retain strong enough immunity for an effective GVT response (Edinger et al. 2003; Trenado et al. 2003) . T R cells thus appear to offer the flexibility of function and potency required for bone marrow transplantation, by balancing the conflicting requirements of immunosuppression and immunopermissiveness.
(c) Tumour immunity
It is now clear that many tumour-associated antigens recognized by autologous T cells are normal selfconstituents and, thus, presumably within the remit of control by self-reactive T R cells. T R cells may even actively be recruited by tumours as a means of immune evasion (Hontsu et al. 2004) . The desirable elimination of tumours by cytotoxic effector T cells may thus be impeded by the action of T R cells and evidence is accumulating that this in fact appears to be the case (Sakaguchi 2000b; Takahashi & Sakaguchi 2003) . Experiments suggest that the simple elimination of T R cells from splenocyte preparations by treatment with anti-CD25 mAb results in productive responses to syngeneic tumours when transferred together to lymphopenic recipients (Onizuka et al. 1999; Shimizu et al. 1999; Sutmuller et al. 2001) . Similarly beneficial effects are seen with the in vivo administration of antibodies. Data appear to suggest that CD25 C CD4 C T R cells interfere with tumour-specific CD8 C responses and their removal, thus enhancing antitumour cytolysis (Chen et al. 2004) . Another fruitful approach may simply be to interfere with T R cell suppression as opposed to depleting them. Signalling through GITR on T R or activated T E cells with either mAbs or specific ligand (GITRL) has been shown to either perturb T R cell suppression or render T E cells resistant to suppression (Shimizu et al. 2002; Stephens et al. 2004) . A therapy embracing both depletion and perturbation of suppression may be the most effective.
In parallel to the experimental data, clinical evidence is emerging that suppressive T R cells are present in increased numbers within tumour draining nodes or within the tumour microenvironment itself (Liyanage et al. 2002; Viguier et al. 2004) . Perturbing T R cell abrogation within the tumour may thus represent a viable treatment strategy.
(d) Microbial immunity
Although the main function of T R cells is thought to be the maintenance of self-tolerance, it is clear that they can also control excessive immune responses to pathogens or inappropriate responses to commensal/mutualistic microbes. As described above, it is well known that severe combined immunodeficiency (SCID) mice transferred with CD25 K CD45RB hi CD4 C cells develop IBD, whereas similarly treated mice lacking intestinal microbes under germ-free conditions show no such immunopathology (Singh et al. 2001) . The sensitivity of the gut in general to perturbation of T R cell number or function intimates the critical involvement that these cells have in the control of immune responses to non-self but otherwise harmless symbiotes. The fundamental nature of this microbial interaction is further suggested by the expression on T R cells of the TLR4 pattern recognition receptor (Caramalho et al. 2003) . It now seems that inflammatory signals, whether host (e.g. IL-6) or pathogen (e.g. lipopolysaccharide, LPS) derived either directly or indirectly, disable T R cell suppressive function (Pasare & Medzhitov 2003; Yamazaki et al. 2003; Fehervari & Sakaguchi 2004) . This suggests a model whereby immune responses are freed-up from T R cell suppression only in the presence of microbial 'danger signals'. In fact, it is becoming increasingly clear that naive T cell responses can only be initiated by DC matured with 'danger signals' such as LPS and that this control is maintained, at least in part, through the action of regulatory cells (Pasare & Medzhitov 2004; Sporri & Reis e Sousa 2005) . T R cells also have a role to play in infectious diseases by blunting overactive and damaging immune responses to pathogens. Evidence for this comes from the rapid and fatal pulmonary inflammation seen following CD25 C CD4 C T R cell depletion during chronic infection with Pneumocystis carinii (Hori et al. 2002) . In this model, immunopathology was mediated by CD25 K CD4 C effector T cells and their damage could be prevented by the presence of CD25 C CD4 C T R cells. It may well be that the necessity to attenuate harmful immunopathology was a key selective pressure leading to the evolution of the T R subset. Another study has examined the role of T R cells during chronic infection with the protozoan parasite Leishmania major (Belkaid et al. 2002) . This model suggested that the long-term persistence of L. major is maintained through the action of T R cells and the removal of CD25 C CD4
C cells resulted in a sterilizing response, i.e. the complete elimination of the parasite. Interestingly, eradication of the parasite in this way prevented immunity to subsequent re-infection and so demonstrated the importance of T R cells for the support of long-term immunological memory. The perseverance of immunological memory has been long-suspected to be mediated by the presence of a small 'antigen depot' and the action of T R cells may thus provide a hitherto unappreciated mechanism by which this can be achieved. This observation with L. major has obvious implications for a vaccine development strategy, i.e. using an adjuvant formulation that enables a reasonable level of T R cell function would encourage the generation of memory. These findings may also throw light on the puzzling nature of the so-called Koch's Phenomenon, i.e. a tuberculous individual is often highly resistant to a new infection yet unable to overcome the original infection. This could be seen as akin to the dual transplant tolerance effect depicted in figure 3 , with the original infection being protected by an established T R population, while fresh infections are subject to the full force of the immune response (Sakaguchi 2003) . Multicellular parasites such as helminths and nematodes provide a particularly compelling area in which to study regulatory cells. Owing to their size such organisms are unable to pursue a classic pathogen evasive strategy of sequestering themselves in host cells, yet they are still able to reside in immunologically exposed environments of their host often for many years. To achieve such a feat they appear to possess multiple and potent mechanisms of immune subversion (Maizels et al. 2004) . There is much evidence that helminths and nematodes trigger a switch from an immunopathological Th1 to a less harmful Th2 response; however, this cannot explain all the data and increasingly it appears that regulatory cell function is being co-opted by such parasites (Yazdanbakhsh et al. 2002) . Basic evidence for the involvement of regulatory cells comes from the observations of elevated lymphocyte IL-10 and TGF-b production following nematode infection (Mahanty et al. 1996) . A further example is seen in the infection of mice with the helminth Schistosoma mansoni. In this case, T R cell-derived IL-10 appears critical for the prevention of immunopathology following such infection and IL-10-producing CD25 C cells can be recovered from parasite-induced granulomas (Hesse et al. 2004) . Several reports have also shown that infection with S. mansoni, along with other microbes, can prevent a host of experimental autoimmune diseases such as T1D, EAE and collagen induced arthritis (CIA) (Cooke et al. 2004) . Interestingly, the T1D-protective effect of S. mansoni is also observed with adult parasite and egg-derived antigens (Cooke et al. 1999; Zaccone et al. 2003) . Importantly, exposure to such antigens may result in the in vivo generation of regulatory cells, since parasite antigen-treated mice were unable to cause diabetes in NOD-SCID recipients following adoptive transfer. More direct evidence for T R cell involvement has been shown in a mouse model of experimental filariasis, where increased expression of Foxp3 and T R cell surface markers are observed in draining lymph nodes following nematode infection (Maizels et al. 2004) . Increasingly, such parasite data are painting a more complex picture of immune evasion, i.e. it is not just a product of simple Th1-Th2 switching but rather the recruitment of T R cell functions. As with many such host-parasite interactions, it is often difficult to disentangle which party benefits from a particular immune response; i.e. is dampening down immunity beneficial to the host through the prevention of immunopathology or is the parasite 'co-opting' the T R cells to ensure its survival/transmission? One thing is clear though: the efficient ability of parasites to engage T R cell functions may be exploited for immunotherapeutic benefit. This has, in fact, already been achieved, with one study demonstrating encouraging results in the treatment of Crohn's disease and IBD following ingestion of Whipworm (Trichuris suis) ova (Summers et al. 2003 (Summers et al. , 2005 . In this particular case, the nematode parasite is by-andlarge non-pathological, but hopefully more advanced therapies should be able to utilize totally harmless parasite-derived antigens with similar efficacy.
A PUTATIVE THERAPEUTIC SCHEME INVOLVING THE USE OF REGULATORY CELLS
Naturally occurring T R cells exhibit several properties that make them potentially useful for therapeutic applications. Firstly, they have a diverse repertoire reactive not only with self-but also with non-self antigens. Secondly, they exhibit a functionally stable phenotype, which appears terminally differentiated for the control of immune responses. Finally, T R cells can be expanded both in vitro and in vivo yet retain a suppressive phenotype. Such properties could be applied to a number of clinically important areas. Figure 5 summarizes a potential therapeutic scheme involving T R cells as applied to the control of transplant rejection. Once a donor is identified the organ is harvested and a source of donor antigen taken, e.g. biopsy material or peripheral blood mononuclear cells (PBMCs), to be used for later expansion of donorspecific regulatory cells. Such donor-specific antigen can be banked if necessary. In the case of a non-solid organ transplant such as bone marrow, recipient T R cells could be pre-mixed with the graft prior to surgery (a), such an enforced localization may reduce the number of T R cells ultimately required for tolerance induction by encouraging in situ regulatory cell expansion. Following grafting, the recipient is put onto a standard immunosuppressive regimen. Two routes of therapy could then potentially be taken. In the first, the recipient undergoes leukapheresis followed by enrichment of T R cells or conversion of conventional T cells to regulatory cells ex vivo, either by gene transduction of FOXP3 or the generation of Tr1-like cells using a pharmacological approach (b). These newly generated regulatory cells are then sorted and expanded on the previously frozen donor-derived antigenic source. To support expansion, growth factors such as IL-2 may need to be added at this stage. The expanded and more importantly donor-specific, regulatory cells are then re-sorted and transferred back to the patient (c). Once an effective population of regulatory cells has been established in the recipient, pharmacological immunosuppression is gradually withdrawn and the graft is maintained long-term by dominant tolerance alone. If one views an organ targeted by autoimmunity as an allograft, then a broadly similar scheme could also be used to alleviate autoimmunity.
As outlined here, such a therapeutic approach seems rather straightforward, however applying it to a real-life situation would present formidable technical challenges. Basically, these could be summarized as problems of number and specificity, i.e. obtaining enough regulatory cells which are reactive with the allograft or, in the case of autoimmunity, self-antigen. 
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These problems could be ameliorated to some extent by the use of living related donors which is becoming an increasingly attractive transplant modality (Prasad et al. 2002; Takada & Tanaka 2004) . The luxury of foreknowing the donor haplotype and time of grafting would give ample opportunity for pre-expanding donor-reactive recipient T R cells. The most desirable scheme would involve the use of an immunosuppressive agent that selectively targeted effector cells, so staving-off rejection, yet allow the expansion of beneficial graft-reactive T R cells (figure 5d and as depicted in figure 4 ). Again, once T R cell mediated suppression had reached a critical threshold of efficacy, immunosuppression could be withdrawn. Immunosuppressive drugs routinely used in transplantation, such as cyclosporin and basiliximab (a depleting anti-IL2R mAb), are probably wholly inappropriate at engendering such a situation, since they would likely impair T R cell function (Sakaguchi & Sakaguchi 1989; Kovarik et al. 1999) . However, numerous animal models have demonstrated the ability of anti-CD4 and to a lesser extent, anti-CD40L mAb to facilitate the in vivo expansion and/or function of T R cells or adaptive regulatory cells (Nathan et al. 2002; Cobbold et al. 2004; .
MAJOR OBSTACLES TO THE USE OF REGULATORY CELLS AS AN IMMUNOTHERAPY
As detailed earlier, a large body of data from murine studies have demonstrated the potent ability of both natural and adaptive regulatory cells to control immune responses under a wide range of clinically important conditions (table 2) . Although, of course, this should be seen as very encouraging, it is now almost axiomatic that many efficacious therapies in the mouse are very difficult to translate into humans or at least if there is a beneficial effect then the results are more subdued. So in order to avoid regulatory cells from becoming a failed 'next big thing', a number of significant hurdles need to be overcome (see table 3 ).
(a) Ex vivo generation of T R cells
The identification of FOXP3 as a critical gene for T R cell development and function was a major advance, since it opened the possibility of in vitro T R cell generation with the obvious clinical benefits that this implies. However, a sober analysis of the experimental details of the mouse work should temper our excitement somewhat. For instance, a simple linear extrapolation of cell numbers used to control immunopathology in the mouse colitis model or skin transplant rejection would require the generation of hundreds of millions of T R cells for a single dose of systemic therapy in a human patient. Relative to the spleen, human peripheral blood yields only small numbers of transduction targets and, furthermore, even if the requisite number of T R cells could be generated then sort times alone would be prohibitive. Clearly, such an approach is impractical and alternatives need to be found, whether theoretical or technical. High-volume magnetic bead-based sorting could be much more practical and would only require the generation of a cell-surface reporter for isolation of T R cell transductants. It is also likely that such exorbitant numbers of T R cells are not required if the antigen is known, such as in the case of transplantation antigens, where there is a high precursor frequency of responders and less-so if there is a defined autoantigen, e.g. myelin basic protein in multiple sclerosis or glutamic dehydrogenase in T1D. AT R cell therapy designed to control autoimmunity may therefore require the identification of real human autoantigens and the cloning of specific cells. A more targeted, rather than systemic, administration of the T R cells may also enable the use of significantly fewer cell numbers. Another technical hurdle concerns the vectors used to introduce Foxp3. All the Foxp3 gene transduction studies in the mouse have been performed using retroviral vectors, which would be an undesirable (c) In vivo expansion/enhancement of T R cells A T R cell-based therapy, while being 'intelligent' in that it is highly targeted as well as flexible, would also be incredibly laborious and expensive to perform. Therefore, from a large-scale therapeutic perspective, the identification of compounds which could specifically target T R cells in vivo by either intensifying/stymieing their function or increasing/decreasing their numbers would be the most desirable approach. This would also make it amenable to the kind of high throughput technologies at which the pharmaceutical and biotech industry excel. Attaining such a goal would require a considerable extension of our knowledge of fundamental T R cell biology. Specifically it would be critical to understand the signalling events both upstream and downstream of FOXP3. How is the FOXP3 gene switched on? How does it exert its effects, is it through direct action or via an intermediary? Finally, the discrepancy between mouse and human as regards the induction of FOXP3 following conventional TCR triggering needs to be resolved Yagi et al. 2004) . If this were to be substantiated, it would alter our understanding of how regulation is generated and maintained in humans, as well as have important implications for the usefulness of FOXP3 as a T R cell specific marker and the validity of mice as a model of human T R cells.
(d) Identification and perturbation of T R cell suppressive mechanisms The inhibition of T R cell-mediated suppression should also be a major therapeutic target. Ideally, this would lead on from the identification of a T R cell-associated molecule specifically involved in suppression, should one actually exist. As outlined in previous sections here, this is still a controversial area. Alternatively, rendering effector cells resistant to suppression could also be a feasible approach. Clearly, identifying target molecules on either effector or T R cells and unambiguously delineating the mechanism of suppression would be absolutely fundamental to the success of any such therapy.
(e) Identification of highly specific human T R cell surface marker(s) Finally, there is a lacuna regarding a highly specific surface marker to identify T R cells. Although several candidate molecules such as CD25 or GITR have been identified, none of them are able to definitively discriminate between activated T cells and T R cells. This is an especially acute problem in humans who naturally have large numbers of activated T cells and where T R cell isolation can be performed definitively only by flow sorting the very highest CD25 C expressers. The ability to confidently identify and isolate T R cells from patients would be fundamental to their clinical exploitation; therefore, the discovery of appropriate cell surface markers should remain a priority.
CONCLUSIONS
Abundant evidence now strongly supports the existence of T R cells as key controllers of selftolerance. It now seems that their suppressive role can be expanded to many areas of immunology, in fact potentially to any scenario, where the suppression and/or tuning of an immune response is required. A strategic manipulation of regulatory cells, whether naturally occurring or adaptive, to dampen or enhance their functions as appropriate promises great clinical benefit. Already manipulation of CD25 C CD4 C T R cells in various animal models has provided encouraging results for the enhancement of tumour immunity, maintenance of allograft tolerance or the control of autoimmunity. Increasingly, studies are also demonstrating the significant roles CD25 C CD4 C T R cells can play in human pathologies as varied as autoimmunity, HIV infection and allergy. Recent advances in our understanding of CD25 C CD4 C T R cell development and important functional markers such as the association with Foxp3/FOXP3, has permitted the accurate isolation and manipulation of these cells in mice and importantly their human counterparts. Understanding the events both upstream and downstream of Foxp3/FOXP3 may enable us to 'tailor-make' large numbers of CD25 C CD4 C T R cells for the specific suppression of immune responses or antagonizing them, where a boost of immunity is required. It is the strong belief of many researchers in this area that T R cells will, in a not-too-distant futurity, become a potent cell based therapy.
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